#ORPH Open Orphan – Board appointment and Annual Report and Notice of AGM June 10, 2022 – Posted in: Blog, Open Orphan (ORPH) – Tags: , , , , ,

Open Orphan plc   (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces the appointment of Martin Gouldstone as an Independent Non-Executive Director of the Company with effect from 8 June 2022. Martin will also Chair the Audit & Risk Committee and will be a member of the Nominations Committee and the Remuneration Committee. ORPH also confirms that the Company’s Annual Report and Accounts for the year ended 31 December 2021 and the Notice of Annual General Meeting (“AGM”) have been posted to shareholders.

 

Martin brings 30 years of corporate development experience in the CRO, healthcare and pharmaceutical sectors, holding  a number of senior roles at healthcare AI businesses.  Martin has expertise in executing multi-billion dollar deals across Europe and the US, architecting end-to-end portfolio out-sourcing deals, and negotiating multi-year research partnerships.

 

Martin is currently Global SVP, Business Development at Owkin, a French-American start-up using artificial intelligence to discover and develop better treatments for unmet medical needs. Previously, Martin has held the roles of Chief Business Officer at both BenevolentAI and Sensyne Health and was a Partner at Results Healthcare, an international M&A advisory firm, where he co-led the company’s healthcare practice. Prior to this, Martin was Head of Life Sciences for BDO UK LLP, Senior Director responsible for M&A and joint venture opportunities in Europe for Quintiles (now IQVIA), and Business Development and Licensing Lead at Confirmant Ltd, Pharmacopeia Inc, Sareum Ltd.

 

Martin holds a BSc in Genetics and has completed a range of post graduate management courses.

 

Yamin ‘Mo’ Khan, Chief Executive Officer of Open Orphan, said:   “I am pleased to welcome Martin to the Board of Open Orphan. Martin has extensive corporate development experience in the CRO, healthcare and pharmaceutical sectors and held a number of senior roles in healthcare AI businesses. I look forward to working closely with Martin as we drive further growth across the business.”

 

Martin Gouldstone, Non-Executive Director, said:  “I am delighted to join the Board of Open Orphan at what is an exciting time for the Company and the   infectious disease market  as it continues to grow significantly post pandemic.  I am delighted to bring my previous three decades of experience in the CRO, healthcare and pharmaceutical industry  to the Company as it continues to build and expand on partnerships with leading global biopharma companies.”

The 2021 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company’s website.

https://www.openorphan.com/investors/reports-and-presentations/year/2022

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 5 July 2022 at 11 am.

 

For further information please contact:

 

Open Orphan plc

+44 (0) 20 7756 1300

Yamin Khan, Chief Executive Officer

Liberum Capital (Nominated Adviser and Joint Broker)

+44 (0) 20 3100 2000

Ben Cryer/ Edward Mansfield/ Phil Walker/ Will King

finnCap plc (Joint Broker)

+44 (0) 20 7220 0500

Geoff Nash / James Thompson / Richard Chambers

Davy (Euronext Growth Adviser and Joint Broker)

+353 (0) 1 679 6363

Anthony Farrell

Walbrook PR (Financial PR & IR)

Paul McManus / Sam Allen /

Louis Ashe-Jepson

+44 (0)20 7933 8780 or  openorphan@walbrookpr.com

+44 (0)7980 541 893 / +44 (0) 7502 558 258 /
+44 (0) 7747 515393